Current therapy of multiple myeloma

Internal Medicine
Robert A Kyle

Abstract

Not all patients who fulfill the minimal criteria for the diagnosis of multiple myeloma should be treated. If a patient is younger than 70 years, autologous peripheral blood stem cell transplantation should be seriously considered. Major challenges for stem cell transplantation are: 1) the inability to eradicate multiple myeloma from the patient, and 2) removal of myeloma cells and their precursors from the reinfused stem cells. Allogeneic transplantation cannot be recommended at present because of the excessive mortality. Nonmyeloablative approaches are promising. There is no evidence that combinations of alkylating agents are superior to melphalan and prednisone. The use of thalidomide and intermittently administered prednisone for maintenance is being explored. New agents include the immunomodulatory drugs, inhibitors of the ubiquitin proteasone pathway such as PS-341, antiangiogenesis drugs including 2-methoxy-estradiol, and farnesyl transferase inhibitors. Management of skeletal complications, hypercalcemia, anemia, infection, spinal cord compression, and renal insufficiency is discussed.

Citations

May 7, 2003·The Lancet Oncology·Ambuj KumarBenjamin Djulbegovic
Oct 26, 2002·InTouch : the Good Health Guide to Cancer Prevention and Treatment·Gail Zyla
Nov 21, 2012·Drug Metabolism and Pharmacokinetics·Katsunori NakamuraTamihide Matsunaga
Feb 8, 2006·Clinical Orthopaedics and Related Research·Edward D Simmons, Yinggang Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

European Heart Journal
Sonia Vélez-RoaPhilippe Unger
International Journal of Cardiology
Robert BlankHans Rickli
Mayo Clinic Proceedings
S Vincent RajkumarMayo Clinic Myeloma, Amyloid, and Dysproteinemia Group
© 2022 Meta ULC. All rights reserved